anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diabetic nephropathy (DN) is a common vascular complication of Type 2 diabetes (T2D) that is associated with increased mortality and poor quality of life.In industrialized countries, DN ranges first among other etiologies of end-stage renal disease (ESRD).Diabetes in Qatar is a serious health issue for the Qatari population since approximately 1/5 of the population has T2D, which is 2-3 times higher than the world average. As observed in other Gulf cooperation council (GCC) countries, obesity and sedentary lifestyle are cornerstones in the development of T2D. Additionally, consanguineous marriages in Qatar contribute to this high prevalence. As a consequence, DN has an enormous burden in terms of management, treatment and especially in renal replacement therapy (RRT) in ESRD in Qatari Population.DN is a glomerular disease defined by increased urinary albumin excretion (UAE), hypertension and decline in the glomerular filtration rate (GFR), all induced by chronic hyperglycemia. However, there are other contributing factors such as genetic predisposition, systemic and intra-renal hemodynamic disturbances, all leading to glomerulosclerosis. All of the known pathways do not explain the complex pathophysiology behind DN. Even different variants of genes described in major GWAS studies have little impact in terms of risk prevention or prognosis of DN. Over the last decade, epigenetics have initiated a new era in Genetic Medicine capable of giving a different approach to human disease.
The invention discloses traditional Chinese medicine for treating qi stagnation and damp obstruction type tympanites. The traditional Chinese medicine is prepared from, by weight, 6 parts of fleshfingered citron flowers, 30 parts of fiveleaf akebia fruits, 25 parts of seven-sisters Japanese rose roots, 8 parts of all-grass of Chinese pennywort, 15 parts of all-grass of circaea quadrisulcata (maxim.) franch.et, 20 parts of great willowherb herbs, 8 parts of silktree albizzia flowers, 20 parts of champion bauhinia leaves, 20 parts of all-grass of polygonum lapathifolium L.var.sali-cidolium sibth., 25 parts of Chinese dicliptera herbs, 15 parts of stamen or pistil of ancients euphorbia, 15 parts of herbs or fruits of little groundcherry, 18 parts of quercus fabri hance fruits, 20 parts of roots or all-grass of lychnis fulgens fisch., 20 parts of all-grass of ammannia auriculata willd., 8 parts of all-grass of veronicastrum stenostachyum (hemsl.) yamazaki, 8 parts of herba moslae, 8 parts of flowers of jasminum officinale L. var. grandiflorum (L.) Kobuski (J. grandiflorum L.), 8 parts of flowers of prunus mume Sieb. et Zucc. var. viridicalyx makino and 10 parts of leaves and stems of true Indigo. All medicinal materials in the formula can cooperate with one another and act in a synergistic mode and work together to achieve the effects of soothing the liver, regulating qi, removing dampness, dispelling stagnation, invigorating the spleen and promoting urination, and qi stagnation and damp obstruction type tympanites can be effectively treated. It is verified through use of 50 patients for years that the effective rate reaches 100%, the treatment effect is good, and the disease does not relapse after being cured.
Within 1 hour prior to chemotherapy, patients receive netupitant/palonosetron hydrochloride PO on day 1. Within 30 minutes prior to chemotherapy, patients also receive dexamethasone PO on days 1-4. Patients also receive placebo PO with chemotherapy Q8H on days 1-4.
phase I: Patients will be vaccinated on day 1,8,15 and 22 of each 28-day treatment cycles. On each vaccination day, the URLC10-117 peptide(1mg) and TTK-567 peptide(1mg) mixed with CpG 7909 (escalating doses: 0, 0.02, 0.1mg/kg) emulsified with Montanide ISA 51 will be administered by subcutaneous injection. Repeated cycles of vaccine will be administered until patients develop progressive disease or unacceptable toxicity, or for maximum 2 cycles, whichever occurs first. In this phase I study, we evaluate the safety and tolerability of URLC10-177, TTK-567 and different doses of CpG7909 to determine the recommended phase II dose of CpG7909.

phase II: Patients will be vaccinated on day 1,8,15 and 22 of each 28-day treatment cycles. On each vaccination day, the URLC10-117 peptide(1mg) and TTK-567 peptide(1mg) mixed with CpG 7909 (recommended dose determined in phase I study) emulsified with Montanide ISA 51 will be administered by subcutaneous injection. Repeated cycles of vaccine will be administered for 2 cycles. In this phase II study, we evaluate the efficacy of this vaccine therapy.
Hepatic tuberculosis (HTB) is rare extrapulmonary tuberculosis that is clinically similar to liver malignancy, making it difficult for correct diagnoses. Pathology is the gold standard for tuberculosis diagnosis. However, there are few reports on the pathological features of HTB. A total of 32 HTB cases were considered and the differences in pathological features and drug resistance were analyzed and compared with those for pulmonary tuberculosis (PTB). Enhanced CT scans showed ring-shaped delayed enhancement during the arterial, venous, and delayed phases. Most HTB cases were single lesions, with the highest incidence in the right lobe, and the average lesion volume was smaller than that of PTB. The frequency of granuloma in pathological changes, the overall share of the lesion area in the HTB group, and the number of foxp3+ cells were significantly higher than in the PTB group. However, no statistically significant differences were observed between the two groups' other pathological features and immune cell numbers. The immune microenvironment of the normal tissues surrounding the lesion was further analyzed. The findings showed that the number of macrophages and foxp3+ cells in the HTB group was significantly higher than in the PTB group. No significant difference in drug resistance was detected between the HTB and PTB groups. In conclusion, there are substantial differences in the characterization of pathological feature and immune microenvironment between HTB and PTB. The frequency of granuloma and subsequent overall share of the lesion area was significantly higher in HTB compared to PTB.
The present invention discloses action of litsea citrate oil in killing parasites on the skin of people and animals, which relates to the action of litsea citrate oil in killing parasites on the skin of people and animals, such as fleas, lice, mites and other arthropod blood sucking insects. Litsea cubeba oil, a liquid carriers, a solid carrier or pesticide are mixed and used to the skin of people and animals, coats, mattresses or environments. The litsea citrate oil contains more than or equal to 65 % of citral, the liquid carrier is lotion or shampoo, and the solid carrier is pearlite solid matter. The raw material of the litsea citrate oil is litsea cubeba which is one kind of traditional Chinese medicinal materials and has the advantages of rich sources, peculiar fragrance, simple preparation and convenient use. The litsea citrate oil and the liquid carrier or the solid carrier are mixed and used to the skin of people and animals. The litsea citrate oil has the strong killing action in killing parasites on the skin of people and animals, the mites, the lice and the fleas and has a certain effect on inhibiting and killing bacteria and fungi on the skin of people and animals. Tests show that the litsea citrate oil has no stimulation to complete skin and eyes of the animals, has slight stimulation to damaged skin which can be automatically recovered after the litsea citrate oil is not used.
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a major 21st-century epidemic. T2DM elevates the risk of myocardial infarction and heart failure while also reducinges survival rates. Recently Ferroptosis has been found to be involved in the development of various cardiovascular diseases. TRPV1 is also a potential therapeutic target for cardioprotection. This study explores whether capsaicin, a transient receptor potential vanilloid receptor 1 (TRPV1) agonist, can prevent diabetic myocardial infarction-induced injury by inhibiting ferroptosis.
METHODS: T2DM model was induced by high-fat diet (HFD) feeding combined with streptozocin (STZ) injections, and the diabetic mice were treated with capsaicin(0.015 %) in their food. Myocardial infarction model was established as well. Mouse' general characteristics, cardiac function, and morphological histology were observed and analyzed. RNA-seq was used to investigate the possible mechanism of injury in AC16 cardiomyocytes cultured with high glucose and hypoxia. In addition, the potential mechanism of capsaicin against injury was further investigated in AC16 cardiomyocytes cultured with high glucose and hypoxia.
RESULTS: The RNA-seq analysis revealed that ferroptosis was associated with cell death induced by high-glucose in combination with hypoxia, and CAP treatment could effectively inhibit ferroptosis to enhance cell survival. In vivo studies demonstrated that CAP treatment significantly improved post-MI cardiac function, attenuated myocardial inflammation and fibrosis. Furthermore, it was observed that CAP reduced ferroptosis levels by activating TRPV1 in the heart, upregulating Nrf2 expression, promoting Nrf2 nuclear translocation and increasing the expression of the Nrf2 downstream molecule Heme oxygenase-1 (HMOX1).
CONCLUSIONS: Dietary capsaicin may inhibit cardiomyocyte ferroptosis through activation of myocardial TRPV1 and Nrf2/HMOX1 signaling pathway, which in turn exerts a protective effect on the myocardium after myocardial infarction in type 2 diabetic mice.
Asthma and chronic obstructive pulmonary disease (COPD) are among the most common chronic respiratory diseases. Chronic inflammation of the airways leads to an increased production of inflammatory markers by the effector cells of the respiratory tract and lung tissue. These biomarkers allow the assessment of physiological and pathological processes and responses to therapeutic interventions. Lung cancer, which is characterized by high mortality, is one of the most frequently diagnosed cancers worldwide. Current screening methods and tissue biopsies have limitations that highlight the need for rapid diagnosis, patient differentiation, and effective management and monitoring. One promising non-invasive diagnostic method for respiratory diseases is the assessment of exhaled breath condensate (EBC). EBC contains a mixture of volatile and non-volatile biomarkers such as cytokines, leukotrienes, oxidative stress markers, and molecular biomarkers, providing significant information about inflammatory and neoplastic states in the lungs. This article summarizes the research on the application and development of EBC assessment in diagnosing and monitoring respiratory diseases, focusing on asthma, COPD, and lung cancer. The process of collecting condensate, potential issues, and selected groups of markers for detailed disease assessment in the future are discussed. Further research may contribute to the development of more precise and personalized diagnostic and treatment methods.
A macromolecular hyaluronic acid is used as a raw material, and is subjected to production processes such as hyaluronidase hydrolysis, heating and inactivation, activated carbon filtration, and spray and dry to obtain an ultra-low molecular weight hyaluronic acid product having an average molecular weight of less than 1200 Da. The product is a mixture of hyaluronic acid disaccharide to dodecaose. The content of hyaluronic acid disaccharide is 5-40%. The content of hyaluronic acid tetrasaccharide is 40-70%. The content of hyaluronic acid hexasaccharide is 10-30%. The content of hyaluronic acid octasaccharide is 1-15%. The content of hyaluronic acid decaose is 1-10%. The content of that higher than hyaluronic acid decaose is less than 6%. Compared with other available low molecular hyaluronic acid, the product has a more significant permeation, moisturizing, and repair promotion capability, and can be widely used in fields of medical products, health care products, cosmetics and the like.
A pelteobagrus fulvidraco epistylis disease therapeutic formula is disclosed. The invention relates to a therapeutic formula for specific treatment of pelteobagrus fulvidraco epistylis disease. The formula has curative effect on infusorian diseases of zoothamuium, carchesium and vorticella, dactylogyriasis, trichodiniasis and ichthyophthiriasis, is also suitable for other aquatic commercial animals such as megalobrama amblycephala and the like, is a biological insecticide for aquatic livestock. The formula has advantages of broad spectrum, high efficiency, low toxicity, no residue, no ''mutagenic, teratogenetic and carcinogenic factors'' and no drug resistance and is easily degradable, and belongs to the field of aquatic fishery drugs. The formula is characterized by being prepared from radix sophorae flavescentis powder (Chinese herbal medicine radix sophorae flavescentis powder), Mannich base essence (effective content 8% of Mannich base essence crystal product), a formaldehyde solution (formalin, analytically pure) and the like. Ratio of the formula is as follows: 1.0-1.5 mg of radix sophorae flavescentis powder, 0.05-0.1 mg of Mannich base essence and 8.0-12.0 mL of the formaldehyde solution. That is to say, contents of radix sophorae flavescentis powder and Mannich base essence in the formaldehyde solution are respectively 0.125-1.25 mg/mL and 0.00625-0.0083 mg/mL.
BACKGROUND: The identification of cancer driver genes from sequencing data has been crucial in deepening our understanding of tumor biology and expanding targeted therapy options. However, apart from the most commonly altered genes, the mechanisms underlying the contribution of other mutations to cancer acquisition remain understudied. Leveraging on our whole-exome sequencing of the largest Asian lung adenocarcinoma (LUAD) cohort (n = 302), we now functionally assess the mechanistic role of a novel driver, PARP4.
METHODS: In vitro and in vivo tumorigenicity assays were used to study the functional effects of PARP4 loss and mutation in multiple lung cancer cell lines. Interactomics analysis by quantitative mass spectrometry was conducted to identify PARP4's interaction partners. Transcriptomic data from cell lines and patient tumors were used to investigate splicing alterations.
RESULTS: PARP4 depletion or mutation (I1039T) promotes the tumorigenicity of KRAS- or EGFR-driven lung cancer cells. Disruption of the vault complex, with which PARP4 is commonly associated, did not alter tumorigenicity, indicating that PARP4's tumor suppressive activity is mediated independently. The splicing regulator hnRNPM is a potentially novel PARP4 interaction partner, the loss of which likewise promotes tumor formation. hnRNPM loss results in splicing perturbations, with a propensity for dysregulated intronic splicing that was similarly observed in PARP4 knockdown cells and in LUAD cohort patients with PARP4 copy number loss.
CONCLUSIONS: PARP4 is a novel modulator of lung adenocarcinoma, where its tumor suppressive activity is mediated not through the vault complex-unlike conventionally thought, but in association with its novel interaction partner hnRNPM, thus suggesting a role for splicing dysregulation in LUAD tumorigenesis.
In man, flecainide acetate produces a dose-related decrease in intracardiac conduction in all parts of the heart with the greatest effect on the His-Purkinje system (H-V conduction). Effects upon atrioventricular (AV) nodal conduction time and intra-atrial conduction times, although present, are less pronounced than those on ventricular conduction velocity. Significant effects on refractory periods were observed only in the ventricle.

Sinus node recovery times (corrected) following pacing and spontaneous cycle lengths are somewhat increased. This latter effect may become significant in patients with sinus node dysfunction. (See WARNINGS.) 

Flecainide acetate causes a dose-related and plasma-level related decrease in single and multiple PVCs and can suppress recurrence of ventricular tachycardia. In limited studies of patients with a history of ventricular tachycardia, flecainide acetate has been successful 30 to 40% of the time in fully suppressing the inducibility of arrhythmias by programmed electrical stimulation. Based on PVC suppression, it appears that plasma levels of 0.2 to 1 mcg/mL may be needed to obtain the maximal therapeutic effect. It is more difficult to assess the dose needed to suppress serious arrhythmias, but trough plasma levels in patients successfully treated for recurrent ventricular tachycardia were between 0.2 and 1 mcg/mL. Plasma levels above 0.7 to 1 mcg/mL are associated with a higher rate of cardiac adverse experiences such as conduction defects or bradycardia. The relation of plasma levels to proarrhythmic events is not established, but dose reduction in clinical trials of patients with ventricular tachycardia appears to have led to a reduced frequency and severity of such events.
The invention discloses a composition and a preparation for treating psoriasis caused by external cold and internal heat and a preparation method thereof, belonging to the technical field of Chinese herbal medicines. The preparation is prepared from herba Ephedrae, radix Saposhnikoviae, cornu Bubali, radix rehmanniae, radix Arnebiae, fructus Gardeniae and flos Sophorae Immaturus. In the recipe, ephedra herb and ledebouriella root, radix sileris, with pungent and warm natured drugs and cold dispelling effects, xuan Qi are used for inducing hair orifices to dissipate internal heat; the buffalo horn, the radix rehmanniae, the lithospermum, the gardenia and the raw sophora flower cool and clear heat in the interior, so that internal heat or blood heat is dissipated from the inside and the outside, and the effect is quicker compared with the common simple blood cooling and heat clearing method. Therapeutic method: pungent and warm natured drugs dispel cold, clear heat and cool blood. The main indications of the prescription are as follows: when the body is scaly papules and erythema in autumn and winter or after the cold in autumn and winter, the skin is damaged more by extending the trunk and limbs. It is accompanied by dry mouth and dry stool, and can be taken frequently. Red tongue with thin or yellow coating and no deficiency in the pulse. The prescription is used for treating psoriasis caused by external cold and internal heat (cold wrapped fire).
FIELD: veterinary. SUBSTANCE: method of prophylaxis involves the administration of vaccine to cattle by subcutaneously route to the neck region at the dose 1.0-1.5 10,0-1,5 cm 3 . Mixed vaccine against anthrax and foot-and-mouth makes immunity in vaccinated animals being simultaneously against two these diseases. Its immunogenicity is comparable with that of monovaccine against anthrax and foot-and-mouth. EFFECT: enhanced effectiveness of vaccine proposed. 3 cl, 1 tbl
If the patient is found to be zinc deficient (serum zinc \< 11.5 μmol/L), the family will be contacted by the RA to commence zinc supplement: zinc citrate (Zinc Lozenges, manufactured by Douglas Laboratories Inc, London, ON, Health Canada NPN 80032476) for 3 months. As per the NPN licence the dose is 10 mg (1 lozenge) orally once a day for children age 4-8 years, and 10 mg twice a day for children age 9-18 years. This should give enough time to restore serum zinc to normal in most patients.
BACKGROUND AND AIMS: In transcatheter aortic valve replacement (TAVR) recipients, the optimal management of concomitant chronic obstructive coronary artery disease (CAD) remains unknown. Some advocate for pre-TAVR percutaneous coronary intervention, while others manage it expectantly. The aim of this study was to assess the impact of varying degrees and extent of untreated chronic obstructive CAD on TAVR and longer-term outcomes.
METHODS: The authors conducted a retrospective cohort study of TAVR recipients from January 2015 to November 2021, separating patients into stable non-obstructive or varying degrees of obstructive CAD. The major outcomes of interest were procedural all-cause mortality and complications, major adverse cardiovascular events, and post-TAVR unplanned coronary revascularization.
RESULTS: Of the 1911 patients meeting inclusion, 75%, 6%, 10%, and 9% had non-obstructive, intermediate-risk, high-risk, and extreme-risk CAD, respectively. Procedural complication rates overall were low (death 0.4%, shock 0.1%, extracorporeal membrane oxygenation 0.1%), with no difference across groups. At a median follow-up of 21 months, rates of acute coronary syndrome and unplanned coronary revascularization were 0.7% and 0.5%, respectively, in the non-obstructive population, rising in incidence with increasing severity of CAD (P < .001 for acute coronary syndrome/unplanned coronary revascularization). Multivariable analysis did not yield a significantly greater risk of all-cause mortality or major adverse cardiovascular events across groups. One-year acute coronary syndrome and unplanned coronary revascularization rates in time-to-event analyses were significantly greater in the non-obstructive (98%) vs. obstructive (94%) subsets (Plog-rank< .001).
CONCLUSIONS: Transcatheter aortic valve replacement can be performed safely in patients with untreated chronic obstructive CAD, without portending higher procedural complication rates and with relatively low rates of unplanned coronary revascularization and acute coronary syndrome at 1 year.
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness. There is also a large inter-individual variability in response to treatments with regard to efficacy and toxicity, and for many drugs, there is also a period of weeks to months to establish its efficacy. Within this context, this project aims to evaluate the importance of monitoring blood levels and salivary drug used in rheumatic autoimmune diseases in the monitoring of adherence to therapy. In addition, this project intends to use the monitoring of drug levels, based on pharmacokinetic studies and pharmacokinetics/pharmacodynamics modeling, to broaden the understanding of the possible cellular, tissue and immunological mechanisms involved in efficacy and adverse effects of these drugs with the prospect of reducing the damage and maintain therapeutic efficacy. The high-performance liquid chromatography (HPLC) coupled to mass spectrometry, which will be used to evaluate hydroxychloroquine, thalidomide, glucocorticoids, is considered the gold standard technology to qualitative and quantitative analysis of drugs in blood and its comparison with the dosage in the saliva is an improvement in simplification of the process. The implementation of this methodology dedicated to research in our center, with the necessary training of human resources, will enable the standardization and availability of this advanced technology to other muldisciplinary projects in various areas of science. For biological agents the focus will be on the understanding the loss of efficacy and the possible role of anti-TNF antibodies using ELISA capture methodology.This thematic project will be divided into four sections with their respective sub-projects according to the medications that will be studied: hydroxychloroquine, thalidomide, biologic agents and glucocorticoids.
Computerised task in which most information is provided by positive outcomes. Completed for 10 mins per day every day for 2 weeks.